Bayer's mineralocorticoid receptor antagonist (MRA) Kerendia has hit the spot in another phase 3 trial that could extend its use as a treatment for patients with chronic kidney disease (CKD).
YORK SPRINGS, Pa. — Bermudian Springs pole vaulter Lily Carlson is fearless. She has all of the cool, calm and collected characteristics similar to any elite athlete, which is why- the bigger the ...
Technology isn’t the biggest challenge. Culture is. by Tim Fountaine, Brian McCarthy and Tamim Saleh Artificial intelligence is reshaping business—though not at the blistering pace many assume. True, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results